Related Experiment Video
Updated: Jan 17, 2026

05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
7.3K
Sex Differences in Adiposity, Body Fat Mobilization and Cardiometabolic Health Following Bariatric Surgery
Lajeunesse-Trempe Fannie1,2, Laurie Marchand3,4, Maëlle Blais3,4,5
1Institut Universitaire de Cardiologie et de Pneumologie de Québec, Québec, Canada. fanny.lajeunesse-trempe.1@ulaval.ca.
Obesity Surgery
|September 22, 2025
Summary
Men show distinct body fat changes after bariatric surgery, with higher abdominal fat and ectopic fat deposition in muscles compared to women, impacting comorbidity remission.
Area of Science:
- Metabolic and Bariatric Surgery
- Obesity Medicine
- Sex Differences in Health
Background:
- Weight management outcomes, including bariatric surgery, can differ between sexes.
- Understanding these sex-based variations is crucial for personalized treatment strategies.
Purpose of the Study:
- To investigate sex-based differences in adiposity, fat mobilization, and obesity-related comorbidities.
- To compare these differences before and after biliopancreatic diversion with duodenal switch (BPD-DS) surgery.
Main Methods:
- Ninety patients (26 men, 64 women) undergoing BPD-DS were analyzed.
- Data collected included medical history, anthropometrics, bioimpedance, and CT scans at baseline and 12 months post-surgery.
- One-way ANOVA assessed sex differences in fat and muscle mobilization.
Main Results:
- Baseline: Men had higher lean mass, abdominal muscle, visceral fat, and ectopic thigh muscle fat than women.
- Post-BPD-DS: Abdominal fat volume and ectopic muscle fat remained higher in men.
- Comorbidity remission rates were numerically lower in men, though not statistically significant.
Conclusions:
- Sex differences in body fat mobilization persist 12 months after BPD-DS.
- Men retain higher abdominal fat and ectopic muscle fat deposition despite similar BMI and overall body composition.
- These findings highlight sex-specific patterns in post-bariatric surgery fat metabolism.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
248
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
248
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Drug Dosing: Obese Patients
225
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
225
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
169
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
169

